With Gondola^®, we went from initial skepticism to surprising results

When we started studying Gondola^®, we were very skeptical of this new device because thinking that a plantar’s foot stimulation could modify the motor activities linked to the central nervous system left the scientific world very bewildered.

However, the clinical observation of the AMPS therapy results surprised us as it improved some parameters of the walk, and the researcher’s curiosity took over the initial perplexity.

We then began to reflect on what role the sole could play in improving these central disorders, and we hypothesized that a peripheral sensory reafferentation could help the patient to improve his motor performance.
Therefore, in collaboration with the Biomedical Campus of Rome, we designed a pilot study to analyze whether cortical and sub-cortical activation modalities were modified in people treated with this type of therapy.

The study led to surprising and unexpected conclusions. In fact, just a single application of the treatment resulted in modifying some areas of the brain involved in the movement.
The future of this approach is to fulfill what we define as unmet needs, which are the motor symptoms that do not respond to currently known therapies and appear in the most advanced stages of the disease, such as Freezing, postural disorders, and balance disorders.